HUNTER CAPITAL AB
NNGM:HUNTER9.84
SEK
-1.26
(-11.35%)
ISIN
SE0022087649
Return %
Stock
S&P 500
1Y
-16.61
14.20
3Y
52.56
81.12
5Y
-93.27
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Jacob Alexander Eriksson
- Sector
- Retail trade
- Industry
- Internet retail
- Address
- Stockholm Sweden
- IPO Date
- Jun 10, 2020
- Website
- huntercapital.se
- Similar Companies
- Business
- Hunter Capital AB (publ) is a Sweden-based investment and corporate development company specializing in active ownership, growth capital allocation, and transaction structuring for small and medium-sized enterprises across the technology and life science sectors. Founded in 2019 and headquartered in Stockholm, Sweden, the company operates across the Nordic region, targeting innovative, high-growth private and public companies seeking capital, operational scale, and strategic pathways to capital market listings. The company provides a comprehensive suite of investment and strategic services, comprising direct equity investments in early-stage and expanding businesses; active portfolio governance, board representation, and operational management support; reverse takeover (RTO) structuring, special-purpose vehicle (SPV) management, and public listing facilitation; corporate restructuring, portfolio divestments, and strategic repositioning; and capital raising, bridge financing, and merger and acquisition (M&A) advisory. Hunter Capital structures its holdings through direct corporate equity stakes, targeted intellectual property assets such as Hunter Capital Dry Eye IPR AB, and dedicated reverse takeover platforms including Hunter Capital RTO 1 AB and Hunter Capital RTO 2 AB. In recent developments, the company executed a major corporate transformation, formally changing its name from Ecore Group AB (publ) to Hunter Capital AB (publ) in January 2024 following shareholder approval, marking a strategic pivot toward technology and life sciences investments. Under the executive leadership of Chief Executive Officer Jacob Eriksson, the company established and listed dedicated reverse takeover vehicles, Hunter Capital RTO 1 AB and Hunter Capital RTO 2 AB, on the Spotlight Stock Market to streamline public transitions for private enterprises. In 2026, Hunter Capital RTO 1 AB entered into a reverse takeover agreement to acquire Danish clinical-stage biotechnology firm ResoTher Pharma A/S, supporting the development of its cardiovascular drug candidate. Additionally, Hunter Capital completed significant strategic asset transfers and launched a mandatory public cash takeover offer for Swedish investment firm C100 AB (publ) after surpassing key ownership thresholds, consolidating its strategic footprint in Nordic technology and life science assets.